This PSNC Briefing provides contractors with guidance for the 2022/23 Pharmacy Quality Scheme (PQS) on meeting the following criteria, which are part of the Respiratory domain:

Use of a spacer in patients aged 5-15 years;
Personalised asthma action plans (PAAPs); and
Referrals for patients using three or more short-acting bronchodilator inhalers without a corticosteroid inhaler in six months.

PSNC Briefing 032/22: Pharmacy Quality Scheme – Asthma referrals

The Briefing also contains four annexes which are available below as separate documents:

Annex A. suggested process for referrals for patients aged 5 years and above who do not have a Personalised Asthma Action Plan (PAAP) and/or children aged 5-15 years who have been prescribed a press and breathe pressurised MDI for asthma without a spacer

Annex B. suggested process for referring patients for an asthma review for patients who have had three or more short-acting bronchodilator inhalers dispensed without a corticosteroid within a six month period

Annex C. Referral form (Word)

Annex C. Referral form  (PDF)

Annex D. Data collection form (Word)

Annex D. Data collection form (PDF)

The post PSNC Briefing 032/22: Pharmacy Quality Scheme – Asthma referrals appeared first on PSNC Website.